The Big Pharma Feud

The Times of India, 15 September 2012

The Crest Edition

Curiously enough, the antagonists in the pharma patents battle seem to be working towards a similar goal – a better deal for patients. But one is fighting for affordability and access, the other is arguing for innovation and discovery.

The conflict is this: innovators want to cover their costs by pricing their medicines high, while generic medicine manufacturers want to roll out cheaper copies of these molecules and provide cheaper medicines to those who cannot afford it.

Click here to read the full article

About these ads
This entry was posted in access to medicines, Compulsory Licensing, Novartis Case, patent evergreening, Sec 3 (d) and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Connecting to %s